BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 18723349)

  • 21. Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives.
    Nagaoka Y; Maeda T; Kawai Y; Nakashima D; Oikawa T; Shimoke K; Ikeuchi T; Kuwajima H; Uesato S
    Eur J Med Chem; 2006 Jun; 41(6):697-708. PubMed ID: 16584813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides.
    Marson CM; Serradji N; Rioja AS; Gastaud SP; Alao JP; Coombes RC; Vigushin DM
    Bioorg Med Chem Lett; 2004 May; 14(10):2477-81. PubMed ID: 15109636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.
    Angibaud P; Arts J; Van Emelen K; Poncelet V; Pilatte I; Roux B; Van Brandt S; Verdonck M; De Winter H; Ten Holte P; Marien A; Floren W; Janssens B; Van Dun J; Aerts A; Van Gompel J; Gaurrand S; Queguiner L; Argoullon JM; Van Hijfte L; Freyne E; Janicot M
    Eur J Med Chem; 2005 Jun; 40(6):597-606. PubMed ID: 15922843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
    Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
    Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
    J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
    Salmi-Smail C; Fabre A; Dequiedt F; Restouin A; Castellano R; Garbit S; Roche P; Morelli X; Brunel JM; Collette Y
    J Med Chem; 2010 Apr; 53(8):3038-47. PubMed ID: 20218673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
    Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
    Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
    Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
    Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
    Su H; Nebbioso A; Carafa V; Chen Y; Yang B; Altucci L; You Q
    Bioorg Med Chem; 2008 Sep; 16(17):7992-8002. PubMed ID: 18701301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors.
    Curtin ML
    Curr Opin Drug Discov Devel; 2004 Nov; 7(6):848-68. PubMed ID: 15595445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
    Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; Cossío FP; Esteller M
    Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
    Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
    Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
    Suzuki T; Ando T; Tsuchiya K; Fukazawa N; Saito A; Mariko Y; Yamashita T; Nakanishi O
    J Med Chem; 1999 Jul; 42(15):3001-3. PubMed ID: 10425110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.